Premium
Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors
Author(s) -
Rodeck Ulrich,
Herlyn Meenhard,
Koprowski Hilary
Publication year - 1987
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.240350406
Subject(s) - monoclonal antibody , growth factor receptor inhibitor , epidermal growth factor , receptor , biology , insulin like growth factor 1 receptor , growth factor , insulin like growth factor receptor , epidermal growth factor receptor , growth factor receptor , insulin like growth factor , cell surface receptor , endocrinology , medicine , antibody , microbiology and biotechnology , cancer research , immunology , biochemistry
Monoclonal antibodies (MAbs) to the human epidermal growth factor (EOF) receptor, the type I insulin‐like growth factor (IGF) receptor, and the nerve growth factor (NGF) receptor were used to study the growth regulation of malignant cells. Anti‐EGF receptor MAb 425 inhibited the growth of A 431 squamous carcinoma cells which express high numbers of EGF receptors on their surfaces. Growth inhibition induced by MAb 425 was accompanied by alterations of the cell‐cycle distribution of these cells, indicating the ability of a monoclonal antibody to act as a biologically active ligand. Growth stimulation of melanoma cells by EGF was unrelated to EGF receptor expression on the cell surface. Insulin‐and IGF‐I‐induced growth stimulation of melanoma cells was inhibited by MAb α‐3 which reacts with the type I IGF receptor. This result indicates that the type I IGF receptor mediated growth stimulation not only by IGF‐I but also by insulin. Normal melanocytes and cells of all stages of tumor progression expressed in tissue culture the receptor for NGF, but no effect on the growth of these cells has been observed.